He Y - Search Results

1

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.

Cheng Y, He Y, Li W, Zhang HL, Zhou Q, Wang B, Liu C, Walding A, Saggese M, Huang X, Fan M, Wang J, Ramalingam SS. Cheng Y, et al. Among authors: he y. Target Oncol. 2021 Mar;16(2):165-176. doi: 10.1007/s11523-021-00794-6. Epub 2021 Feb 5. Target Oncol. 2021. PMID: 33544337 Free PMC article. Clinical Trial.

2

Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes.

Chen H, Yao W, Chu Q, Han R, Wang Y, Sun J, Wang D, Wang Y, Cao M, He Y. Chen H, et al. Among authors: he y. Cancer Lett. 2015 Dec 1;369(1):97-102. doi: 10.1016/j.canlet.2015.08.024. Epub 2015 Sep 1. Cancer Lett. 2015. PMID: 26341687

3

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators. Mok TS, et al. Among authors: he y. N Engl J Med. 2017 Feb 16;376(7):629-640. doi: 10.1056/NEJMoa1612674. Epub 2016 Dec 6. N Engl J Med. 2017. PMID: 27959700 Free PMC article. Clinical Trial.

4

A Multicenter Double-blind Phase II Study of Metformin With Gefitinib as First-line Therapy of Locally Advanced Non-Small-cell Lung Cancer.

Li KL, Li L, Zhang P, Kang J, Wang YB, Chen HY, He Y. Li KL, et al. Among authors: he y. Clin Lung Cancer. 2017 May;18(3):340-343. doi: 10.1016/j.cllc.2016.12.003. Epub 2016 Dec 22. Clin Lung Cancer. 2017. PMID: 28065465 Free article. Clinical Trial.

5

EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study.

Han B, Tjulandin S, Hagiwara K, Normanno N, Wulandari L, Laktionov K, Hudoyo A, He Y, Zhang YP, Wang MZ, Liu CY, Ratcliffe M, McCormack R, Reck M. Han B, et al. Among authors: he y. Lung Cancer. 2017 Nov;113:37-44. doi: 10.1016/j.lungcan.2017.08.021. Epub 2017 Sep 1. Lung Cancer. 2017. PMID: 29110846

6

Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib.

Wang Y, Li L, Han R, Jiao L, Zheng J, He Y. Wang Y, et al. Among authors: he y. Lung Cancer. 2018 Apr;118:105-110. doi: 10.1016/j.lungcan.2018.02.007. Epub 2018 Feb 13. Lung Cancer. 2018. PMID: 29571987 Free article.

7

Metformin synergistically enhances the antitumor activity of the third-generation EGFR-TKI CO-1686 in lung cancer cells through suppressing NF-κB signaling.

Pan YH, Lin CY, Lu CH, Li L, Wang YB, Chen HY, He Y. Pan YH, et al. Among authors: he y. Clin Respir J. 2018 Dec;12(12):2642-2652. doi: 10.1111/crj.12970. Epub 2018 Nov 9. Clin Respir J. 2018. PMID: 30307719

8

Protective autophagy decreases osimertinib cytotoxicity through regulation of stem cell-like properties in lung cancer.

Li L, Wang Y, Jiao L, Lin C, Lu C, Zhang K, Hu C, Ye J, Zhang D, Wu H, Feng M, He Y. Li L, et al. Among authors: he y. Cancer Lett. 2019 Jun 28;452:191-202. doi: 10.1016/j.canlet.2019.03.027. Epub 2019 Mar 22. Cancer Lett. 2019. PMID: 30910592

9

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.

Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators. Mok TSK, et al. Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4. Lancet. 2019. PMID: 30955977 Clinical Trial.

10

Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial.

Li L, Jiang L, Wang Y, Zhao Y, Zhang XJ, Wu G, Zhou X, Sun J, Bai J, Ren B, Tian K, Xu Z, Xiao HL, Zhou Q, Han R, Chen H, Wang H, Yang Z, Gao C, Cai S, He Y. Li L, et al. Among authors: he y. Clin Cancer Res. 2019 Dec 1;25(23):6967-6975. doi: 10.1158/1078-0432.CCR-19-0437. Epub 2019 Aug 14. Clin Cancer Res. 2019. PMID: 31413010 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

37,185 results

Search Page